Condition: High-Risk Prostate Cancer · Sponsor: VA Office of Research and Development
The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk localized prostate cancers that are most resistant to standard treatments. This is a phase II research study. For this study, capivasertib, the study drug, will be taken with intensified androgen deprivation drugs (iADT; abiraterone and leuprolide) prior to radical prostatectomy. This study drug treatment will be evaluated to see if it is effective in shrinking and destroying prostate cancer tumors prior to surgery and to further evaluate its safety prior to prostate cancer surgery.
This description comes directly from the study's public registry record.
Ryan P Kopp, MD · (503) 220-8262 · ryan.kopp@va.gov
Always discuss trial participation with your own doctor first.
| VA Greater Los Angeles Healthcare System, West Los Angeles, CA | West Los Angeles, California, United States | Recruiting |
| James J. Peters VA Medical Center, Bronx, NY | The Bronx, New York, United States | Recruiting |
| VA Portland Health Care System, Portland, OR | Portland, Oregon, United States | Recruiting |
| Ralph H. Johnson VA Medical Center, Charleston, SC | Charleston, South Carolina, United States | Recruiting |
| South Texas Health Care System, San Antonio, TX | San Antonio, Texas, United States | Terminated |
| VA Puget Sound Health Care System Seattle Division, Seattle, WA | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05593497